

Special Issue

Personalized Medicine of Coronary Artery Disease

Message from the Guest Editor

Personalized medicine is developing fast, and new data are emerging in huge amounts. This might enable the right risk assessment, diagnosis, prevention, and therapy specifically tailored to the unique characteristics of the individual, thus enhancing the quality of life as well as public health. Therefore, the aim of this Special Issue is to present recent developments in personalized medicine and coronary artery disease. We invite authors to submit original clinical studies, reviews, meta-analyses, as well as case reports focused on the individualization of the prevention, diagnosis, and treatment of coronary artery disease, including myocardial infarction. We are soliciting not only genetic studies, but all papers on the broadly understood personalized medicine, including papers on novel drugs, medical devices, or approaches dedicated to special subsets of patients.

Guest Editor

Dr. Jacek Bil

Department of Invasive Cardiology, Centre of Postgraduate Medical Education, Central Clinical, Hospital of the Ministry of Interior and Administration, Woloska 137 Street, 02-507 Warsaw, Poland

Deadline for manuscript submissions

closed (28 February 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/51020

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).